Sanofi’s Dengue Vaccine Is Effective in Study – WSJ.comPosted: August 10, 2012
The vaccine could still fail in further testing. Sanofi is conducting additional trials involving another 31,000 people in 10 countries in Latin America and Asia. The vaccine uses weakened forms of the dengue virus to raise the body’s immune response, a type of inoculation known as a “live attenuated vaccine.”
If Sanofi’s vaccine does make it to market, the company will be able to produce about 100 million doses a year at a factory in France—enough for about 33 million children, since each child requires three doses, Sanofi spokesman Pascal Barollier said Wednesday. The WHO estimates there are currently between 50 million and 100 million new dengue infections world-wide each year.